{"id":6478,"date":"2024-04-08T12:19:04","date_gmt":"2024-04-08T12:19:04","guid":{"rendered":"https:\/\/www.nfp-drugs.bg\/en\/?p=6478"},"modified":"2025-07-24T14:36:05","modified_gmt":"2025-07-24T14:36:05","slug":"prevalence-of-hiv-and-hepatitis-b-c-infection-among-people-who-inject-drugs-in-2023-data-from-sphtdaa-laboratory-sofia","status":"publish","type":"post","link":"https:\/\/www.nfp-drugs.bg\/en\/prevalence-of-hiv-and-hepatitis-b-c-infection-among-people-who-inject-drugs-in-2023-data-from-sphtdaa-laboratory-sofia\/","title":{"rendered":"Prevalence of HIV and hepatitis B\/C infection among people who inject drugs in 2023 (data from SPHTDAA Laboratory, Sofia)"},"content":{"rendered":"\n
\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
\n
Prevalence of psychoactive substance use
Prevalence of medication use
Prevalence of drug use<\/a>
Drug prevention
Treatment supply<\/a>
Treatment demand
Health consequences<\/a>
Harm reduction<\/a>
Drug-related crimes<\/a>
Drug market<\/a>
Drug use and prison<\/a>
Monitoring of publications<\/a>
Attitudes to legal framework changes<\/a><\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n
\n

Prevalence of HIV and hepatitis B\/C infection among people who inject drugs (PWID) in 2023<\/strong><\/p>\n\n\n\n

<\/td>HIV<\/strong> (anti-HIV)<\/strong><\/td>Hepatitis \u0412 (HbsAg)<\/strong> <\/strong><\/td>Hepatitis \u0421 (anti-HCV)<\/strong><\/td><\/tr>
Total number of PWID who were tested<\/strong><\/td>203<\/strong><\/td>203<\/strong><\/td>204<\/strong><\/td><\/tr>
Males<\/td>145<\/td>144<\/td>145<\/td><\/tr>
Females<\/td>58<\/td>59<\/td>59<\/td><\/tr>
Number of PWID with a positive test result<\/strong><\/td>32<\/strong><\/td>30<\/strong><\/td>175<\/strong><\/td><\/tr>
Males<\/td>29<\/td>25<\/td>129<\/td><\/tr>
Females<\/td>3<\/td>5<\/td>46<\/td><\/tr>
Proportion positive (%)<\/strong><\/td>15.8%<\/strong><\/td>14.8%<\/strong><\/td>85.8%<\/strong><\/td><\/tr>
Males<\/td>20.0%<\/td>17.4%<\/td>89.0%<\/td><\/tr>
Females<\/td>5.2%<\/td>8.5%<\/td>78.0%<\/td><\/tr><\/tbody><\/table>
Note: PWID are defined as people who have injected drugs at some point in their life. <\/sub><\/strong><\/figcaption><\/figure>\n\n\n\n

Prevalence of HIV and hepatitis B\/C infection among people who inject drugs (PWID) in 2023 (by age groups)<\/strong><\/p>\n\n\n\n

<\/td>HIV<\/strong> (anti-HIV)<\/strong><\/td>Hepatitis \u0412 (HbsAg)<\/strong> <\/strong><\/td>Hepatitis \u0421 (anti-HCV)<\/strong><\/td><\/tr>
Age <25<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>2<\/td>2<\/td>2<\/td><\/tr>
Number of PWID with a positive test result<\/td>0<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
Age 25-34<\/strong><\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>16<\/td>16<\/td>16<\/td><\/tr>
Number of PWID with a positive test result<\/td>3<\/td>4<\/td>14<\/td><\/tr>
Proportion positive (%)<\/td>18.75%<\/td>25.0%<\/td>87.5%<\/td><\/tr>
Age > 34<\/strong><\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>185<\/td>185<\/td>186<\/td><\/tr>
Number of PWID with a positive test result<\/td>29<\/td>26<\/td>161<\/td><\/tr>
Proportion positive (%)<\/td>15.7%<\/td>14.1%<\/td>86.6%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Prevalence of HIV and hepatitis B\/C infection among people who inject drugs (PWID) in 2023 (by years since first injection)<\/strong><\/p>\n\n\n\n

<\/td>HIV<\/strong> (anti-HIV)<\/strong><\/td>Hepatitis \u0412 (HbsAg)<\/strong> <\/strong><\/td>Hepatitis \u0421 (anti-HCV)<\/strong><\/td><\/tr>
<2 years since first injection<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>1<\/td>1<\/td>1<\/td><\/tr>
Number of PWID with a positive test result<\/td>0<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
2 to 4 years since first injection<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>1<\/td>1<\/td>1<\/td><\/tr>
Number of PWID with a positive test result<\/td>0<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
5 to 9 years since first injection<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>7<\/td>7<\/td>7<\/td><\/tr>
Number of PWID with a positive test result<\/td>1<\/td>1<\/td>2<\/td><\/tr>
Proportion positive (%)<\/td>14.3%<\/td>14.3%<\/td>28.6%<\/td><\/tr>
10 or more years since first injection<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>194<\/td>194<\/td>195<\/td><\/tr>
Number of PWID with a positive test result<\/td>31<\/td>29<\/td>173<\/td><\/tr>
Proportion positive (%)<\/td>16.0%<\/td>14.9%<\/td>88.7%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Prevalence of HIV and hepatitis B\/C infection among people who inject drugs (PWID) in 2023 (by primary drug)<\/strong><\/p>\n\n\n\n

<\/td>HIV<\/strong> (anti-HIV)<\/strong><\/td>Hepatitis \u0412 (HbsAg)<\/strong> <\/strong><\/td>Hepatitis \u0421 (anti-HCV)<\/strong><\/td><\/tr>
PWID with primary drug opioids<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>189<\/td>189<\/td>190<\/td><\/tr>
Number of PWID with a positive test result<\/td>32<\/td>27<\/td>175<\/td><\/tr>
Proportion positive (%)<\/td>16.9%<\/td>14.3%<\/td>92.1%<\/td><\/tr>
PWID with primary drug cocaine<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>3<\/td>3<\/td>3<\/td><\/tr>
Number of PWID with a positive test result<\/td>0<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr>
PWID with primary drug stimulants other than cocaine<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>7<\/td>7<\/td>7<\/td><\/tr>
Number of PWID with a positive test result<\/td>0<\/td>3<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>0.0%<\/td>42.9%<\/td>0.0%<\/td><\/tr>
PWID with primary drug other<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>4<\/td>4<\/td>4<\/td><\/tr>
Number of PWID with a positive test result<\/td>0<\/td>0<\/td>0<\/td><\/tr>
Proportion positive (%)<\/td>0.0%<\/td>0.0%<\/td>0.0%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Prevalence of HIV and hepatitis B\/C infection among people who inject drugs (PWID) in 2023 (by contact with drug treatment<\/strong> in the last 12 months)<\/strong><\/p>\n\n\n\n

<\/td>HIV<\/strong> (anti-HIV)<\/strong><\/td>Hepatitis \u0412 (HbsAg)<\/strong> <\/strong><\/td>Hepatitis \u0421 (anti-HCV)<\/strong><\/td><\/tr>
PWID who have been in contact with drug treatment services in the last 12 months<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>176<\/td>176<\/td>177<\/td><\/tr>
Number of PWID with a positive test result<\/td>32<\/td>25<\/td>165<\/td><\/tr>
Proportion positive (%)<\/td>18.2%<\/td>14.2%<\/td>93.2%<\/td><\/tr>
PWID who have not been in contact with drug treatment services in the last 12 months<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>26<\/td>26<\/td>26<\/td><\/tr>
Number of PWID with a positive test result<\/td>0<\/td>5<\/td>10<\/td><\/tr>
Proportion positive (%)<\/td>0.0%<\/td>19.2%<\/td>38.5%<\/td><\/tr>
PWID with missing information on drug treatment contact<\/strong><\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>1<\/td>1<\/td>1<\/td><\/tr>
Number of PWID with a positive test result<\/td>0<\/td>0<\/td>0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Prevalence of HIV and hepatitis B\/C infection among people who inject drugs (PWID) in 2023 (by imprisonment)<\/strong><\/p>\n\n\n\n

<\/td>HIV<\/strong> (anti-HIV)<\/strong><\/td>Hepatitis \u0412 (HbsAg)<\/strong> <\/strong><\/td>Hepatitis \u0421 (anti-HCV)<\/strong><\/td><\/tr>
PWID ever in prison<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>21<\/td>21<\/td>21<\/td><\/tr>
Number of PWID with a positive test result<\/td>7<\/td>7<\/td>19<\/td><\/tr>
Proportion positive (%)<\/td>33.3%<\/td>33.3%<\/td>90.5%<\/td><\/tr>
PWID never in prison<\/strong><\/td><\/td><\/td><\/td><\/tr>
Number of PWID who were tested<\/td>182<\/td>182<\/td>183<\/td><\/tr>
Number of PWID with a positive test result<\/td>25<\/td>23<\/td>156<\/td><\/tr>
Proportion positive (%)<\/td>13.7%<\/td>12.6%<\/td>85.2%<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n<\/div>\n\n\n\n

Source: State Psychiatric Hospital for Treatment of Drug Addiction and Alcoholism (SPHTDAA), Sofia, NFP, NCPHA.<\/em><\/strong><\/p>\n\n\n\n

Data for 2022<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Prevalence of psychoactive substance usePrevalence of medication usePrevalence of drug useDrug preventionTreatment supplyTreatment demandHealth consequencesHarm reductionDrug-related crimesDrug marketDrug use and prisonMonitoring of publicationsAttitudes to legal framework changes Prevalence of HIV and hepatitis B\/C infection among people who inject drugs (PWID) in 2023 HIV (anti-HIV) Hepatitis \u0412 (HbsAg) Hepatitis \u0421 (anti-HCV) Total number of PWID who […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84,86],"tags":[],"_links":{"self":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6478"}],"collection":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/comments?post=6478"}],"version-history":[{"count":3,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6478\/revisions"}],"predecessor-version":[{"id":7498,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/6478\/revisions\/7498"}],"wp:attachment":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media?parent=6478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/categories?post=6478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/tags?post=6478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}